Influence of Plasma Cholesterol and Triglyceride Concentrations and Eritoran (E5564) Micelle Size on its Plasma Pharmacokinetics and Ex Vivo Activity Following Single Intravenous Bolus Dose Into Healthy Female Rabbits

2007 ◽  
Vol 25 (1) ◽  
pp. 176-182 ◽  
Author(s):  
Kishor M. Wasan ◽  
Verica Risovic ◽  
Olena Sivak ◽  
Stephen D. Lee ◽  
Douglas X. Mason ◽  
...  
Keyword(s):  
Bolus Dose ◽  
Ex Vivo ◽  
Plasma Cholesterol ◽  
Intravenous Bolus ◽  
Intravenous Bolus Dose ◽  
Micelle Size ◽  
Healthy Female ◽  
Plasma Pharmacokinetics

Pharmacokinetics of an intravenous bolus dose of clonidine in children undergoing surgery

2020 ◽  
Vol 30 (5) ◽  
pp. 607-613
Author(s):  
Bettina N. Nielsen ◽  
Brian J. Anderson ◽  
Lars Falcon ◽  
Steen W. Henneberg ◽  
Torsten Lauritsen ◽  
...  
Keyword(s):  
Bolus Dose ◽  
Intravenous Bolus ◽  
Intravenous Bolus Dose

Feasibility, Effectiveness and Safety of Prehospital Intravenous Bolus Dose Nitroglycerin in Patients with Acute Pulmonary Edema

2020 ◽  
Vol 24 (6) ◽  
pp. 844-850 ◽  
Author(s):  
Casey Patrick ◽  
Brad Ward ◽  
Jordan Anderson ◽  
Kelly Rogers Keene ◽  
Elizabeth Adams ◽  
...  
Keyword(s):  
Pulmonary Edema ◽  
Bolus Dose ◽  
Acute Pulmonary Edema ◽  
Intravenous Bolus ◽  
Intravenous Bolus Dose

Effects of an Intraoperative Intravenous Bolus Dose of Dexmedetomidine on Remifentanil-Induced Postinfusion Hyperalgesia in Patients Undergoing Thyroidectomy

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Zhijie Wu ◽  
Junjie Yu ◽  
Qihua Lin ◽  
Huiting Li ◽  
Tianhua Zhang ◽  
...  
Keyword(s):  
Bolus Dose ◽  
Intravenous Bolus ◽  
Intravenous Bolus Dose

Effect of a 15-Minute Infusion of DDAVP on the Pharmacokinetics and Pharmacodynamics of ™REVASC during a Four-Hour Intravenous Infusion in Healthy Male Volunteers

1997 ◽  
Vol 77 (01) ◽  
pp. 127-132 ◽  
Author(s):  
Dipti M Amin ◽  
Timothy G K Mant ◽  
Stephen M Walker ◽  
Roger Kerry ◽  
Peter Lloyd ◽  
...  
Keyword(s):  
Intravenous Infusion ◽  
Bolus Dose ◽  
Intravenous Bolus ◽  
Healthy Male ◽  
Pharmacokinetics And Pharmacodynamics ◽  
Serious Adverse Events ◽  
Constant Rate ◽  
Bleeding Episodes ◽  
Plasma Pharmacokinetics ◽  
Partial Reversal

SummaryPlasma pharmacokinetics, effect on coagulation parameters, and safety and tolerability of an intravenous infusion of ™REVASC before, during and after a DDAVP infusion were investigated.Twelve healthy volunteers were given an intravenous bolus dose followed by a constant rate four-hour infusion of ™REVASC. Fifteen-minute infusions of 0.9% saline and DDAVP were started two and three hours respectively after the start of the ™REVASC infusion.Plasma ™REVASC concentrations were not affected by either the saline or DDAVP infusion. ™REVASC infusion produced an increase in APTT which plateaued between 0.5 and 3 hours. After the DDAVP infusion there was a tendency towards a new lower plateau whilst the ™REVASC infusion continued. There were no serious adverse events or bleeding episodes throughout the study.In conclusion, the co-administration of intravenous DDAVP has no effect on the plasma pharmacokinetics of ™REVASC and partially reverses the ™REVASC-induced increase in APTT. This may represent a role for DDAVP in the partial reversal of anticoagulation induced by ™REVASC.

Sign in / Sign up

Export Citation Format

Share Document